Aratana Therapeutics’ new appetite stimulant for dogs, Entyce, will begin shipping to U.S. veterinarians in late October.
The Leawood, Kansas, company reported Oct. 13 that Entyce (capromorelin oral solution) will be available in 10-, 15- and 30-milliliter bottles.
Administered once a day, the flavored oral therapeutic is formulated to mimic the hunger hormone ghrelin, bind to receptors in the hypothalamus and signal the feeling of hunger, according to Aratana.
“Nutrition is so imperative, veterinarians and pet owners often use appetite as a fifth vital sign and go to great lengths to address inappetence,” said Ernst Heinen, DVM, Ph.D., Aratana’s chief development officer. “Entyce was developed specifically to stimulate appetite and provides the first therapeutic based on the natural physiology of appetite.”
Entyce earned U.S. Food and Drug Administration approval in May 2016. Aratana stated that the FDA Center for Veterinary Medicine recently approved “the transfer and scale-up of manufacturing.”
Entyce is Aratana’s third canine product. Already on the market are Galliprant (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis and Nocita (bupivacaine liposome injectable suspension) for post-surgery pain relief.